What Is the Best Medication for Depression and Anxiety?

No single medication is universally “best” for treating both depression and anxiety, but selective serotonin reuptake inhibitors (SSRIs) are the most common starting point and the drug class with the broadest evidence for both conditions. A large meta-analysis comparing twelve newer antidepressants found that escitalopram and sertraline offered the strongest combination of effectiveness and tolerability, while mirtazapine and venlafaxine also ranked highly for efficacy.¹ The real question is less “which pill is best” and more “which pill is best for you,” because the choice hinges on your specific symptom profile, side-effect tolerance, other medications, and life circumstances.

SSRIs as the Default Starting Point

SSRIs work by increasing serotonin availability in the brain, and they are prescribed more than any other class of antidepressant for the simple reason that they treat both depression and anxiety with a relatively mild side-effect profile. The most commonly prescribed SSRIs include escitalopram, sertraline, fluoxetine, paroxetine, citalopram, and fluvoxamine. When researchers have compared them head to head for anxiety symptoms in depressed patients, moderate evidence suggests that the SSRIs do not meaningfully differ from one another in how well they reduce anxiety.² In other words, if one SSRI doesn’t suit you, switching to another from the same family is a reasonable next step.

That said, some SSRIs do pull ahead in specific comparisons. Escitalopram, for example, showed a greater reduction in both depression and anxiety scores than paroxetine over 24 weeks in patients who started treatment with high anxiety levels. Patients on paroxetine were also roughly twice as likely to drop out of the study, partly because of side effects.³ The broader meta-analysis mentioned earlier reinforced this, finding that escitalopram and sertraline led to fewer people quitting treatment than several competitors, including paroxetine, fluvoxamine, and venlafaxine.¹ Acceptability matters because a medication you can actually stay on for months is far more useful than one that works slightly better on paper but makes you feel lousy enough to quit.

SNRIs and Why a Prescriber Might Choose One Instead

Serotonin-norepinephrine reuptake inhibitors (SNRIs) affect two brain chemicals instead of one, adding norepinephrine to the serotonin activity of SSRIs. The most widely used SNRIs are venlafaxine and duloxetine. They are considered first-line treatments for several anxiety disorders and have shown efficacy that is generally comparable to SSRIs.⁴ A meta-analysis looking at dose-response patterns in anxiety disorders found no significant differences in efficacy between SSRIs and SNRIs, and both classes showed their greatest benefits in social anxiety disorder.⁵

So why would a clinician reach for an SNRI? One common reason is that the norepinephrine component can help with fatigue, difficulty concentrating, and chronic pain, all of which frequently accompany depression and anxiety. Duloxetine, in particular, has a separate indication for certain chronic pain conditions. Venlafaxine ranked among the most efficacious antidepressants in the large Lancet meta-analysis, though it also had higher dropout rates than escitalopram or sertraline. In practice, the choice between an SSRI and an SNRI often comes down to whether you have co-occurring symptoms that the dual mechanism might address.

Mirtazapine for Sleep and Appetite Problems

Mirtazapine works differently from SSRIs and SNRIs. It blocks certain serotonin and histamine receptors rather than inhibiting reuptake, and that histamine-blocking action is what makes it powerfully sedating, especially at lower doses. For people whose depression and anxiety come with insomnia and weight loss, mirtazapine can be a smart pick because it directly addresses those symptoms. One study in cancer patients found that only the mirtazapine group showed improvements in early, middle, and late insomnia, along with reductions in both anxiety and depression scores.⁶ In another trial comparing mirtazapine to paroxetine in depressed patients with anxiety, both drugs ended up equally effective by week eight, but mirtazapine users showed faster improvement in anxiety scores during the first two weeks.⁷

The trade-off is weight gain. While most antidepressants are associated with a modest gain of roughly three to four kilograms over six to twelve months, mirtazapine tends to cause more significant weight gain earlier in treatment.⁸ For someone who is underweight or struggling to eat, that is a feature. For someone already overweight, it can be a dealbreaker.

Bupropion and the Anxiety Misconception

Bupropion is unusual among antidepressants because it acts on dopamine and norepinephrine rather than serotonin. It is well known for being weight-neutral, having minimal sexual side effects, and helping with smoking cessation. Clinicians have long been taught that bupropion worsens anxiety, and many avoid prescribing it to anxious patients. The evidence increasingly suggests that concern is overblown.

A head-to-head trial of bupropion versus sertraline (a standard SSRI) in depressed patients found no difference in their effects on anxiety symptoms, with both groups reaching a clinically meaningful reduction in anxiety at around four weeks.⁹ A more recent 12-week naturalistic study concluded that bupropion was just as effective as SSRIs for anxiety in patients with major depression, and that the common clinical worry about bupropion worsening anxiety was “unfounded.”¹⁰ A review did note that bupropion’s stimulating properties can provoke anxiety at higher doses, and that SSRIs may still be preferable when severe anxiety is the dominant feature.¹¹ If sexual side effects or weight gain from an SSRI are driving you to consider alternatives, bupropion deserves a conversation with your prescriber rather than automatic dismissal.

Newer Antidepressants and Cognitive Symptoms

Vortioxetine is a newer antidepressant with a multimodal mechanism: it inhibits serotonin reuptake like an SSRI but also directly modulates several serotonin receptor subtypes. What makes it stand out is the evidence around cognitive function. Depression and anxiety often impair concentration, memory, and decision-making, and most older antidepressants do little to improve those symptoms even when mood gets better. Vortioxetine is the first antidepressant shown to improve both depression and cognitive symptoms in clinical studies.¹² If brain fog and forgetfulness are among your most bothersome symptoms, vortioxetine is worth discussing, though it tends to be more expensive than generic SSRIs.

How Long Before You Feel Better

One of the most frustrating aspects of antidepressant treatment is the delay. Most SSRIs, SNRIs, and atypical antidepressants take weeks to months to reach their full effect.¹³ Many people start to notice modest improvement in sleep, energy, or irritability within the first two weeks, but the full antidepressant and anti-anxiety benefit typically takes four to six weeks at an adequate dose. This lag is one reason people give up on a medication prematurely, and it is also why clinicians sometimes add a short-term medication for the early weeks.

Benzodiazepines (like lorazepam, clonazepam, or alprazolam) work almost immediately and are sometimes prescribed alongside an antidepressant during this waiting period. An older Cochrane review found that combining a benzodiazepine with an antidepressant produced a small advantage over antidepressants alone at one and four weeks, but that advantage disappeared by six to twelve weeks.¹⁴ The combination also made patients less likely to drop out of treatment. The concern with benzodiazepines is dependence: among people who started a benzodiazepine at the same time as an antidepressant, about one in eight was still taking the benzodiazepine long-term.¹⁵ Most guidelines recommend benzodiazepines only for short-term bridging, not ongoing use.

When the First Medication Doesn’t Work

Roughly a third of people with depression respond well to the first antidepressant they try. Another third improve partially, and the remaining third see little benefit. When the first or second attempt fails, clinicians typically either switch to a different class or add a second medication on top of the antidepressant. Adding a low-dose atypical antipsychotic (such as aripiprazole or quetiapine) is one well-studied strategy. Research supports quetiapine augmentation for treatment-resistant depression, especially when anxiety or insomnia are present alongside depression.¹⁶ Aripiprazole augmentation has also shown significant reductions in anxiety and depression scores in patients with anxious depression who had not responded adequately to antidepressants alone.¹⁷

For severe, treatment-resistant cases, ketamine-based therapies represent a genuine breakthrough. Intravenous ketamine has produced rapid reductions in both depression and anxiety, with patients meeting criteria for anxious distress actually showing a greater improvement in depression scores than less-anxious patients after four infusions.¹⁸ Esketamine (the nasal spray form, marketed as Spravato) has similarly shown significant benefits regardless of whether the patient had comorbid anxiety.¹⁹ These treatments require in-office administration and monitoring, and they are generally reserved for people who have tried multiple other options without success.

Older antidepressant classes, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), also retain a role for treatment-resistant patients. Though they carry more side effects and drug interactions, some experts argue they should continue to play a part in modern treatment, especially when newer drugs have failed.²⁰

Side Effects That Often Drive the Decision

In many cases, the “best” medication is the one whose side effects you can live with, because the differences in efficacy between most first-line options are modest. The major side-effect categories that shape prescribing decisions include:

Sexual dysfunction: Common with SSRIs and SNRIs. Bupropion and mirtazapine are much less likely to cause this problem.
Weight gain: Most antidepressants cause a few kilograms of gain over months. Mirtazapine is associated with more gain, and earlier in treatment. Bupropion is generally weight-neutral or mildly weight-reducing.
Sedation: Mirtazapine is the most sedating first-line option, which helps insomnia but can cause daytime drowsiness. SSRIs and SNRIs are less sedating but can still cause fatigue in some people.
Activation and jitteriness: Some people, particularly in the first week or two of an SSRI or SNRI, experience increased anxiety, restlessness, or insomnia. Starting at a low dose and increasing slowly helps reduce this.
Nausea: Common with SSRIs and SNRIs early in treatment, usually temporary.

Antidepressant-induced sexual dysfunction deserves particular emphasis because it is often underreported. Patients may not volunteer the information, and clinicians may not ask. It is also the side effect most likely to lead someone to stop their medication. If this becomes an issue, switching to bupropion or mirtazapine, or adding an adjunct medication, are common strategies.⁸

Withdrawal When You Stop

Antidepressant withdrawal symptoms are more common than many patients realize. A meta-analysis estimated that roughly 43% of people experience some form of withdrawal, with symptoms typically appearing within two weeks of stopping. Treatment duration matters: people on antidepressants for over 24 weeks had withdrawal rates above 50%, compared to about 35% for those on treatment for six to twelve weeks. Tapering the dose rather than stopping abruptly reduced the rate somewhat, though not as dramatically as you might hope. Risk factors included being female, younger, experiencing side effects early in treatment, and taking higher doses.²¹ The practical takeaway is straightforward: never stop an antidepressant cold turkey. Work with your prescriber on a gradual taper, especially if you have been on the medication for several months or longer.

Children, Adolescents, and Suicidality

In young people under 18, the medication landscape is narrower and carries a specific safety concern. All antidepressants in the United States carry a black box warning about increased risk of suicidal thoughts and behavior in children and adolescents. A meta-analysis of observational studies found that antidepressant use in this age group was associated with a higher risk of suicide attempts, with SSRIs carrying a roughly 28% increased relative risk compared to no antidepressant use.²² The risk of completed suicide, however, was not statistically significant in that analysis, and the absolute numbers remain small. When comparing individual SSRIs to one another, no meaningful differences in suicidal act rates were found between fluoxetine, citalopram, fluvoxamine, paroxetine, or sertraline.²³

Fluoxetine remains the most commonly recommended antidepressant for adolescents because it has the longest track record and the most data in that age group. Close monitoring during the first weeks of treatment is considered essential, and the warning should not be interpreted to mean that no young person should take antidepressants. Untreated depression itself carries significant suicide risk, and for moderate to severe cases, medication combined with therapy is often the best-supported approach.

Pregnancy and Breastfeeding

Choosing an antidepressant during pregnancy involves balancing the risks of medication exposure against the risks of untreated maternal depression, which itself carries consequences including preterm birth, low birth weight, and impaired bonding. The older SSRIs (sertraline, fluoxetine, citalopram) and venlafaxine appear to be free of teratogenic risk based on available data.²⁴ Some reports suggest an association between SSRI exposure late in pregnancy and mild, self-limiting newborn adaptation symptoms like jitteriness or feeding difficulty, though it remains hard to separate the effects of the medication from those of the underlying depression.²⁵ Bupropion and mirtazapine have less safety data in pregnancy and are generally not recommended as first-line options during this period.

During breastfeeding, most newer antidepressants produce very low or undetectable levels in the infant’s blood. The highest infant plasma levels have been reported for fluoxetine, citalopram, and venlafaxine, so sertraline and paroxetine are often preferred for nursing mothers when medication is needed.²⁶

A separate development specific to postpartum depression is zuranolone, a GABA-modulating neurosteroid approved by the FDA in 2023. Unlike traditional antidepressants, zuranolone is taken for just 14 days. Two phase III trials found it produced clinically meaningful improvement in depressive symptoms, with benefits appearing as early as day three and persisting through day 45 after the treatment course ended.²⁷ It represents an entirely different approach from anything else on the market, targeting the GABA system rather than serotonin or norepinephrine. Zuranolone’s current approval is limited to postpartum depression, not general depression or anxiety.

Older Adults

Depression and anxiety in people over 65 present unique prescribing challenges. Metabolism slows with age, so drugs stay in the system longer and side effects can be amplified. Both TCAs and SSRIs should be used cautiously in older adults who are at risk for falls, because both classes can impair balance.²⁸ SSRIs are generally preferred over TCAs for older adults because they lack the cardiovascular and anticholinergic effects that make TCAs particularly risky in this population. Escitalopram and sertraline are frequently chosen because of their relatively clean interaction profiles. Paroxetine, by contrast, tends to be avoided in older adults because of its stronger anticholinergic properties. The principle is to start at a lower dose, increase more slowly, and monitor closely for side effects that a younger patient might tolerate without issue.

Can Genetic Testing Tell You Which Medication to Take

Pharmacogenomic testing, where a cheek swab analyzes genes involved in drug metabolism, has become increasingly marketed to patients and clinicians. The idea is appealing: test your DNA, skip the trial-and-error, and go straight to the right medication. The reality is more modest. A large trial found that pharmacogenomic testing reduced the prescribing of medications predicted to have problematic drug-gene interactions, and there were small positive effects on symptom remission early on, but no significant difference in remission rates by 24 weeks compared to usual care.²⁹

A different randomized trial reported more encouraging results, with the pharmacogenomic testing group showing higher remission rates at both eight weeks (24% vs. 15%) and twelve weeks (31% vs. 20%), along with fewer side effects.³⁰ A comprehensive review, however, concluded that there is currently little evidence to support routine use of available pharmacogenomic tests for predicting antidepressant response.³¹ The testing is better at identifying which drugs you might metabolize poorly (and therefore suffer more side effects from) than at predicting which drug will actually make you feel better. It can be a useful tool, especially if you have already failed several medications, but it is not the magic shortcut that advertising sometimes implies.

Why Medication Alone Is Often Not Enough

The strongest treatment outcomes for depression with anxiety consistently come from combining medication with structured psychotherapy, particularly cognitive behavioral therapy (CBT). A trial comparing CBT plus duloxetine (an SNRI) to duloxetine alone for generalized anxiety disorder found that the combination produced nearly double the response rate at four weeks (57% vs. 24%) and roughly triple the remission rate (about 22% vs. 6%). These advantages held at eight weeks and, to a lesser degree, at three-month follow-up.³² Therapy provides coping strategies and changes in thinking patterns that medication alone cannot, and the combination addresses both the biological and psychological dimensions of these conditions. If your prescriber recommends medication but does not discuss therapy, it is worth bringing up yourself.

The Placebo Response in Depression Treatment

Something that rarely comes up in a prescriber’s office but substantially affects how you should interpret antidepressant research is the size of the placebo response. In clinical trials for depression, patients given a sugar pill improve dramatically. Across treatment modalities used for treatment-resistant depression, the pooled placebo effect size was large.³³ Some analyses have argued that most of the benefit seen with antidepressants is attributable to placebo response, and that the drug-specific effect beyond placebo is small.³⁴

This does not mean antidepressants are worthless. It means that the act of seeking help, receiving a diagnosis, being monitored regularly, and expecting improvement all produce real neurobiological changes. It also means that the difference between any two active antidepressants is generally small compared to the difference between treatment and no treatment. If you and your prescriber are stuck debating escitalopram versus sertraline, the honest truth is that starting either one and pairing it with therapy is likely to matter far more than which pill you pick.